PEIJIA-B (09996) achieved a revenue of approximately 3.5-3.6 billion yuan in the first half of the year, representing a year-on-year growth of about 16.2%-19.5%.

PEIJIA-B (09996) announced that the group's revenue in the first half of 2025 was approximately 3.5 billion to 3.6 billion yuan, an increase of about 16.2% to 19.5% year-on-year. The announcement stated that the main drivers of the continued revenue growth are as follows: -The group's market share in the Transcatheter Aortic Valve Replacement (TAVR) market in China further expanding and the product mix tilting towards newly launched high-end products; and the strong performance of key neurointerventional products, such as deepening market penetration of existing advantages products such as DCwire microguidewire, Tethys AS thrombus aspiration catheter, and Fastunnel delivery type balloon dilatation catheter; and the successful launch of the newly approved YonFlow blood flow-guided mesh stent. During the reporting period, the group's comprehensive TAVR portfolio (including TaurusOne, TaurusElite, and the newly launched TaurusMax) expanded to over 70 new healthcare institutions, covering a total of over 720 healthcare institutions as of June 30, 2025. During the reporting period, the total number of TAVR implants exceeded 2,050 units, an increase of about 18.8% year-on-year.